Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.
about
Mitigating the cardiovascular and renal effects of NSAIDsThe cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confoundingCardiovascular hazard of selective COX-2 inhibitors: myth or reality?Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteersIncreased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production.Use of genetic data to guide therapy in arterial disease.Prostacyclin in systemic lupus and anticardiolipin syndrome.Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis.Inhibition of eicosanoid biosynthesis by glucocorticoids in humans.Internalization and sequestration of the human prostacyclin receptor.Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene.Prostaglandins, thromboxanes and leukotrienes in clinical medicineBiological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man.Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.Adventures in vascular biology: a tale of two mediators.Understanding the NSAID related risk of vascular events.Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in manThe choreography of cyclooxygenases in the kidney.Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.Current concepts in cyclooxygenase inhibition in breast cancer.Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid productionEffect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammationAntagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbitProstaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.Association of cyclooxygenase-2 genetic variant with cardiovascular disease.Effect of an Ethanol Extract of Scutellaria baicalensis on Relaxation in Corpus Cavernosum Smooth MuscleMinimal regulation of platelet activity by PECAM-1.Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smokingRelationship between cyclooxygenase-2 inhibition and thrombogenesis.Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine.Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.Assessments of arterial stiffness and endothelial function using pulse wave analysisMast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice.Pain management for dentists: the role of ibuprofen.Cardiovascular risk of selective cyclooxygenase-2 inhibitors.
P2860
Q27022837-8B86ED19-ED98-4D2E-B40E-45F20A5548FFQ28177082-58213A7A-1031-48AB-8940-E1EB9B453B0AQ28198746-F0818F14-7B64-41B3-9850-A03E7976DA57Q28218884-0E833E54-135F-4146-BCBC-5D5A8766DF82Q30423459-4D47D20E-7642-4AA2-902B-D407BD1D53BDQ30978916-1FAAB7CD-5B2C-4EB7-91F9-F8964AFBD259Q33557479-8B69941D-5235-4B15-816B-E93A78478B60Q33582896-60C99258-E523-4BE6-82A3-D7319447FB7EQ33783999-F21D9549-78FF-41B2-B196-4519362EAC57Q33908973-C41E83CE-2CE5-4E67-A2A3-64864A1EF2ADQ34141454-0C92193C-8EEB-4286-A9F1-959DB4261045Q34192889-159A123A-74DE-49CC-8244-68832A0A3E57Q34245387-97B5DA26-C817-412A-91AC-F176F5824926Q34285416-B6903AC1-B481-4692-AC3C-F0FF5C581FCBQ34417007-79826470-491E-4FB6-A01D-A937D1F2C42AQ34417120-5AA28C7E-023B-45A0-BF44-C3D937707E41Q34515584-E5E0A26B-92DD-40F7-A3A4-4E3C68EE2046Q34546560-45D75920-EA1F-4519-B76C-28C4AB498E45Q34565519-08BD7FEF-E99E-4B5C-B757-C3741318FA29Q34717860-818543BB-08B7-4D4C-B118-2605BDA49E7AQ34730034-DB3D7DED-B532-4FBB-87CD-67D8F38E086DQ34969789-58E2FA14-1052-4AB5-9942-89DD2CAAB2BCQ35029268-E673695F-75D6-4D0D-A1CE-19FF86C62268Q35070737-56BC726D-C256-4128-97F3-BF9B52F67300Q35159985-155F4E86-B3C2-4BE5-AB10-C39D9B9C22BCQ35287418-3D5C9297-E7EB-402C-9F89-76D55C912FE1Q35593380-F4665521-8D11-4560-B86A-2E69CB9F23BCQ35608507-38843E81-24ED-48B9-8D89-B2916C1CE2DCQ35660091-DBDA1624-D7B2-41CB-91BC-7F21A05EB65AQ35689559-65FC34E7-D771-4781-A791-E8C578B6CF5AQ35704273-3DE13520-BE5D-4260-BD3D-245EAB7EE045Q35750211-4ABDCE2F-6823-4538-A490-8926128EF640Q35763802-E1103DAA-CB2C-4A5F-A760-EA8031BE5828Q35769055-903A7CEA-262A-4D84-AFA8-5A5CA9178BD2Q35788328-97AAF05D-BC3F-434E-A752-7257DFDA85ABQ35848746-3E620381-1DEE-489B-B818-DA30D76A9262Q35990833-9516AC64-2988-47EC-89D1-DA9F6EAF7D5DQ36042453-26733062-2C87-4C25-9C43-EFC803EF55D0Q36148700-A24EE67D-3274-475A-B049-F81CCB351F2FQ36167666-E8237E6E-2340-4B21-93E0-42C390B8281F
P2860
Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Increased prostacyclin biosynt ...... rosis and platelet activation.
@en
type
label
Increased prostacyclin biosynt ...... rosis and platelet activation.
@en
prefLabel
Increased prostacyclin biosynt ...... rosis and platelet activation.
@en
P2093
P1476
Increased prostacyclin biosynt ...... rosis and platelet activation.
@en
P2093
FitzGerald GA
Pedersen AK
P304
P356
10.1056/NEJM198404263101701
P407
P577
1984-04-01T00:00:00Z